The whole-genome landscape of medulloblastoma subtypes
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and ‘enhancer hijacking’ events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma. Genomic analysis of 491 medulloblastoma samples, including methylation profiling of 1,256 cases, effectively assigns candidate drivers to most tumours across all molecular subgroups. Medulloblastomas are highly malignant brain tumours that develop during childhood. Paul Northcott and colleagues analysed the whole-genome sequences of 491 medulloblastomas in order to characterize the genomic landscape across tumours and identify new drivers and mutational signatures. Their integrative genomic analyses, including methylation profiling of 1,256 medulloblastomas, identifies subgroup-specific driver mutations and suggests additional tumour subtypes. The authors assign driver mutations to a high proportion of the less well characterized Group 3 and Group 4, which together contribute to more than 60% of all medulloblastomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The overlap observed between the G3 and G4 tumors with respect to MYC amplification supports the working hypothesis that these medulloblastomas are not easily separable in part because they originate from a shared cerebellar progenitor cell pool, with each group arising from arrest at different points along a developmental stage continuum (8, 23).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Methylation array–based classification studies have categorized the G3/G4-2, G3/G4-3, and G3/G4-4 molecular subgroups as G3; the G3/G4-1, G3/G4-5, and G3/G4-6 subgroups as a mix of G3 and G4; and the G3/G4-7 and G3/G4-8 subgroups as primarily G4 (8).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 2×
“T 0) 42 .”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657 · cited 1×
“The relatively recent recognition of consensus MB subgroups has rapidly changed the way MB is studied in the research setting and how it is diagnosed and treated in the clinic 39 .”
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621 · cited 1×
“The functional effect of the mutations was annotated using Annovar 43 and the variants were assessed for their confidence and split into somatic and non-somatic calls.”
Principal components analysis corrects for stratification in genome-wide association studies
Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006) · Nature Genetics · doi:10.1038/ng1847 · Cited by 10,248
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“…previously detected in MB 16 and has been linked with underlying BRCA1 and BRCA2 mutations in breast, aggressive prostate, and pancreatic cancers 16,17 , was unexpectedly observed in most of the patients with Group 3 and Group 4 MB, and a subset of patients with SHH MB. Additional…”
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Cited by
Items 301–400 of 998
Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment
Hill, R. M., Plasschaert, S. L. A., Timmermann, B., Dufour, C., Aquilina, K., Avula, S., Donovan, L., Lequin, M. H., Pietsch, T., Thomale, U. W., et al. (2021) · Cancers · doi:10.3390/cancers14010126 · Cited by 33
Self-citationAdult Medulloblastoma: Updates on Current Management and Future Perspectives
Franceschi, E., Giannini, C., Furtner, J., Pajtler, K. W., Asioli, S., Guzman, R. G., Seidel, C., Gatto, L., & Hau, P. (2022) · Cancers · doi:10.3390/cancers14153708 · Cited by 29
“Based on analysis of DNA methylation and transcriptomic data, these molecularly heterogeneous subgroups among group 3 and group 4 MBs were identified with distinct clinical and genetic associations [56].”
BackgroundMethodCooney, T., Lindsay, H., Leary, S. E. S., & Wechsler‐Reya, R. J. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100861 · Cited by 32
Pomella, S., Cassandri, M., D’Archivio, L., Porrazzo, A., Cossetti, C., Phelps, D. A., Perrone, C., Pezzella, M., Cardinale, A., Wachtel, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44130-0 · Cited by 25
In silico analysis of long non-coding RNAs in medulloblastoma and its subgroups
Joshi, P. K., Jallo, G. I., & Perera, R. J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104873 · Cited by 29
A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma
Wang, D., Pierce, A. M., Veo, B. L., Fosmire, S. P., Danis, E. P., Donson, A. M., Venkataraman, S., & Vibhakar, R. (2021) · Cancers · doi:10.3390/cancers13030387 · Cited by 25
“However, a previous study reported that FBXW7 mutations are not frequently observed in group 3 MB, implying that wild-type FBXW7 is deregulated by a different mechanism [28].”
BackgroundCellular immunotherapy for medulloblastoma
Schakelaar, M. Y., Monnikhof, M., Crnko, S., Pijnappel, E. W., Meeldijk, J., ten Broeke, T., & Bovenschen, N. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac236 · Cited by 32
Mice Expressing Myc in Neural Precursors Develop Choroid Plexus and Ciliary Body Tumors
Shannon, M. L., Fame, R. M., Chau, K. F., Dani, N., Calicchio, M. L., Géléoc, G. S. G., Lidov, H. G. W., Alexandrescu, S., & Lehtinen, M. K. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.02.009 · Cited by 25
Molecular characterization of medulloblastomas with extensive nodularity (MBEN)
Korshunov, A., Sahm, F., Stichel, D., Schrimpf, D., Ryzhova, M. V., Zheludkova, O., Голанов, А. В., Lichter, P., Jones, D., von Deimling, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1840-0 · Cited by 26
“To evaluate the methylation status of the MGMT promoter region, we evaluated beta values of probes cg12434587 and cg12981137 using the MGMT_STP27 logistic regression model [13].”
BackgroundMethodResultSelf-citationBailey, S., Jacobs, S. A., Kourti, M., Massimino, M., André, N., Doz, F., Dufour, C., Vennarini, S., Padovani, L., Aquilina, K., et al. (2024) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2024.100205 · Cited by 40
Oncogene aberrations drive medulloblastoma progression, not initiation
Okonechnikov, K., Joshi, P. K., Körber, V., Rademacher, A., Bortolomeazzi, M., Mallm, J., Vaillant, J., da Silva, P. B. G., Statz, B., Sepp, M., et al. (2025) · Nature · doi:10.1038/s41586-025-08973-5 · Cited by 30
“High-level amplifications affecting MYC or MYCN (identified from methylation/WGS copy number profiles) and duplications of SNCAIP , leading to overexpression of PRDM6 (identified from WGS SV calling), were additionally integrated from a previous global data analysis 2 .”
InfluentialSelf-citation3D Chromosomal Landscapes in Hematopoiesis and Immunity
Kloetgen, A., Thandapani, P., Tsirigos, A., & Aifantis, I. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.07.003 · Cited by 26
Sarić, N., Selby, M. P., Ramaswamy, V., Kool, M., Stockinger, B., Högstrand, C., Williamson, D., Marino, S., Taylor, M. D., Clifford, S. C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56876-z · Cited by 32
Self-citationTargeting Notch Trafficking and Processing in Cancers
Pagliaro, L., Sorrentino, C., & Roti, G. (2020) · Cells · doi:10.3390/cells9102212 · Cited by 25
“The discovery of the oncogenic role of NOTCH in T-ALL anticipated the identification of NOTCH aberrations in solid tumors, such as lung adenocarcinoma [119], medulloblastoma [120], melanoma [121], colon cancer [122,123], and more frequently, in breast cancer [35,124].”
BackgroundBiological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead
Shrestha, S., Morcavallo, A., Gorrini, C., & Chesler, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.694320 · Cited by 29
“The majority of these tumours (86%) harbour activating mutations in b-catenin (CTNNB1), a central orchestrator of the canonical WNT pathway (33, 37, 38), or mutations in the tumour suppressor gene APC (71%) (39).”
BackgroundMethodInfluentialLiquid biopsy: early and accurate diagnosis of brain tumor
Yi, Z., Qu, C., Zeng, Y., & Liu, Z. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04011-3 · Cited by 31
Greuter, L., Frank, N. A., Guzman, R. G., & Soleman, J. (2022) · Cancers · doi:10.3390/cancers14112683 · Cited by 28
Implementation of DNA Methylation Array Profiling in Pediatric Central Nervous System Tumors
White, C. L., Kinross, K. M., Moore, M. K., Rasouli, E., Strong, R., Jones, J. M., Cain, J. E., Sturm, D., Sahm, F., Jones, D., et al. (2023) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.06.013 · Cited by 24
Self-citationBreckwoldt, M. O., Bode, J., Sahm, F., Krüwel, T., Solecki, G. M., Hahn, A., Wirthschaft, P., Berghoff, A. S., Haas, M., Venkataramani, V., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01004 · Cited by 24
“Spatial information and growth dynamics are important aspects of tumor biology that get lost in the plethora of genetic and epigenetic studies that are currently revolutionizing the field (Jones et al., 2012; Plaisier et al., 2016; Northcott et al., 2017).”
BackgroundSelf-citationMYC modulators in cancer: a patent review
Wang, X., Su, X., Cheng, S.-Q., Zhi-yin, S., Huang, Z., & Ou, T. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1612878 · Cited by 28
“breast cancer [34], ovarian carcinoma [34], acute myeloid leukemia [34], chronic myelogenous leukemia [34], Hodgkin’s and Burkitt’s lymphoma [20,34], diffuse large Bcell lymphoma [35,36], prostate cancer [37], colon cancer [38,39], gastric cancer [40], primary central nervous system lymphoma [41], glioblastoma [42], m…”
BackgroundUpregulation of the chromatin remodeler HELLS is mediated by YAP1 in Sonic Hedgehog Medulloblastoma
Robinson, M. H., Maximov, V. D., Lallani, S. B., Farooq, H., Taylor, M. D., Read, R. D., & Kenney, A. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-50088-1 · Cited by 26
Self-citationEmbryonal Tumors of the Central Nervous System
Blessing, M. M., & Alexandrescu, S. (2020) · Surgical pathology clinics · doi:10.1016/j.path.2020.01.003 · Cited by 25
Goddard, J., Castle, J., Southworth, E., Fletcher, A., Crosier, S., Martín‐Guerrero, I., García-Ariza, M., Navajas, A., Masliah‐Planchon, J., Bourdeaut, F., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02566-0 · Cited by 27
Self-citationLong, Y., Wendel, J. F., Zhang, X., & Wang, M. (2023) · Trends in Plant Science · doi:10.1016/j.tplants.2023.11.009 · Cited by 26
Systematic review and meta‐analysis of bulk RNAseq studies in human Alzheimer's disease brain tissue
Heberle, B. A., Fox, K. L., Libermann, L. L., Xavier, S. R. M., Dallarosa, G. T., Santos, R. C., Fardo, D. W., Viola, T. W., & Ebbert, M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70025 · Cited by 35
“29 In addition, RNAseq characterized tumor subtypes and identified new potential drivers for medulloblastoma, 30 a highly malignant childhood brain tumor.”
Gajjar, A. J., Mahajan, A., Bale, T., Bowers, D. C., Canan, L., Chi, S. N., Cluster, A. S., Cohen, K. J., Cole, B., Coven, S. L., et al. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.0012 · Cited by 36
Self-citationBriel-Pump, A., Beez, T., Ebbert, L., Remke, M., Weinhold, S., Sabel, M., & Sorg, R. V. (2018) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2018.11.002 · Cited by 24
EHMT2/G9a as an Epigenetic Target in Pediatric and Adult Brain Tumors
Souza, B. K., Freire, N. H., Jaeger, M. D. C., de Farias, C. B., Brunetto, A. L., Brunetto, A. T., & Roesler, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011292 · Cited by 27
“Two subgroups are defined by mutations leading to aberrant activation of the Wingless (WNT) and Sonic hedgehog (SHH) pathways, whereas Group 3 MB display amplification of genes involved in the Notch and transforming growth factor-β (TGFβ) pathways, and Group 4 show a prominent representation of genes involved in regul…”
BackgroundWu, H., Wei, M., Li, Y., Ma, Q., & Zhang, H. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.910543 · Cited by 29
Vo, T., Balderson, B., Jones, K., Ni, G., Crawford, J., Millar, A., Tolson, E., Singleton, M., Mulay, O., Walters, S. B., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01185-4 · Cited by 25
Clinical outcome of pediatric medulloblastoma patients with Li–Fraumeni syndrome
Kolodziejczak, A. S., Guerrini‐Rousseau, L., Masliah‐Planchon, J., Ecker, J., Selt, F., Mynarek, M., Obrecht, D., Sill, M., Autry, R. J., Stutheit-Zhao, E., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad114 · Cited by 26
Self-citationKMT2D suppresses Sonic hedgehog-driven medulloblastoma progression and metastasis
Sanghrajka, R. M., Koche, R. P., Medrano, H., Nagar, S. E., Stephen, D. N., Lao, Z., Bayin, N. S., Ge, K., & Joyner, A. L. (2023) · iScience · doi:10.1016/j.isci.2023.107831 · Cited by 27
TULIPs decorate the three-dimensional genome of PFA ependymoma
Johnston, M. J. G., Lee, J. J. Y., Hu, B., Nikolić, A., Hasheminasabgorji, E., Baguette, A., Paik, S., Chen, H., Kumar, S. A., Chen, C. C. L., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.023 · Cited by 25
Self-citationDoussouki, M. E., Gajjar, A. J., & Chamdine, O. (2019) · Future Neurology · doi:10.2217/fnl-2018-0030 · Cited by 29
Self-citationTCF4 (E2-2) harbors tumor suppressive functions in SHH medulloblastoma
Hellwig, M., Lauffer, M. C., Bockmayr, M. L., Spohn, M., Merk, D. J., Harrison, L., Ahlfeld, J., Kitowski, A., Neumann, J. E., Ohli, J., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01982-5 · Cited by 25
Self-citationWeischenfeldt, J., & Ibrahim, D. M. (2023) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2023.102048 · Cited by 21
Self-citationSlika, H., Alimonti, P., Raj, D., Caraway, C. A., Alomari, S., Jackson, E. M., & Tyler, B. (2023) · Cancers · doi:10.3390/cancers15153889 · Cited by 23
“Herein, GFI1 and GFI1B oncogenes are abnormally expressed in both group 3 and group 4 tumors in a mutually exclusive fashion [25].”
BackgroundMethodInfluentialPediatric embryonal brain tumors in the molecular era
Li, B. K., Al-Karmi, S. A., Huang, A., & Bouffet, É. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1714439 · Cited by 30
Zhu, S., Lin, F., Chen, Z., Jiang, X., Zhang, J., Yang, Q., Chen, Y., & Wang, J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.563882 · Cited by 23
Self-citationPre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
Buzzetti, M., Morlando, S., Solomos, D., Mehmood, A., Cox, A. W. I., Chiesa, M., D’Alessandra, Y., Garofalo, M., Topham, C. H., & Leva, G. D. (2021) · Scientific Reports · doi:10.1038/s41598-021-84082-3 · Cited by 29
Immunosuppression in Medulloblastoma: Insights into Cancer Immunity and Immunotherapy
Audi, Z. F., Saker, Z., Rizk, M., Harati, H., Fares, Y., Bahmad, H. F., & Nabha, S. M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00874-9 · Cited by 23
Non-Canonical Splicing and Its Implications in Brain Physiology and Cancer
Pitolli, C., Marini, A., Sette, C., & Pagliarini, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052811 · Cited by 28
Lalchungnunga, H., Hao, W., Maris, J. M., Asgharzadeh, S., Henrich, K., Westermann, F., Tweddle, D. A., Schwalbe, E. C., & Strathdee, G. R. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01988-z · Cited by 25
“Mutation data, derived from whole genome and whole-exome sequencing [18] H.”
BackgroundMethodKling, M. J., Kesherwani, V., Mishra, N. K., Alexander, G. R., McIntyre, E. M., Ray, S., Challagundla, K. B., Joshi, S. S., Coulter, D. W., & Chaturvedi, N. K. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02530-y · Cited by 26
“Studies have revealed that damaging germline mutations in known cancer predisposition genes are rare in Group 3 or Group 4 MBs [6], suggesting that dysregulated epigenetic pathways might be critical in the pathogenesis of such MBs.”
BackgroundInfluentialLinke, F., Johnson, J. E. C., Kern, S., Bennett, C., Lourdusamy, A., Lea, D., Clifford, S. C., Merry, C. L. R., Stolnik, S., Alexander, M. R., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01496-4 · Cited by 28
“For the comparison between MB samples and normal cerebellum the R2: MegaSampler tool (Pfister data set [22] compared to the 9 cerebellum samples from the Roth353 dataset [23]) was used.”
MethodGodbole, S., Voß, H., Gocke, A., Schlumbohm, S., Schumann, Y., Peng, B., Mynarek, M., Rutkowski, S., Dottermusch, M., Dorostkar, M. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50554-z · Cited by 28
Self-citationZomerman, W. W., Plasschaert, S. L. A., Conroy, S., Scherpen, F. J. G., Boer, T. M.-D., Lourens, H. J., Llobet, S. G., Smit, M. J., Slagter‐Menkema, L., Seitz, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.089 · Cited by 22
“Future advancements in the proteomics field will elucidate whether additional medulloblastoma protein-signaling subtypes exist, similar to the diversification of molecular subtypes that followed from advanced (epi)genetic profiling (Cavalli et al., 2017; Northcott et al., 2017).”
Besharat, Z. M., Sabato, C., Pò, A., Gianno, F., Abballe, L., Napolitano, M., Miele, E., Giangaspero, F., Vacca, A., Catanzaro, G., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01281 · Cited by 23
Ghavi-Helm, Y. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.09.010 · Cited by 23
da Silva, L. S., Mançano, B. M., de Paula, F. E., dos Reis, M. B., de Almeida, G. C., Matsushita, M., Carlos, A., Evangelista, A. F., Saggioro, F. P., Serafini, L. N., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.04.207 · Cited by 22
Self-citationLiquid Biomarkers for Pediatric Brain Tumors: Biological Features, Advantages and Perspectives
Madlener, S., & Gojo, J. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040254 · Cited by 24
“Moreover, certain medulloblastoma subtypes harbor somatic alterations such as TERT Promoter-, CNNB1, PTCH1 or other mutations which could be leveraged for liquid biopsy monitoring [15].”
BackgroundGroup 3 medulloblastoma transcriptional networks collapse under domain specific EP300/CBP inhibition
Shendy, N. A. M., Bikowitz, M. J., Sigua, L. H., Zhang, Y., Mercier, A. L., Khashana, Y., Nance, S., Liu, Q., Delahunty, I. M., Robinson, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47102-0 · Cited by 28
“One of the most aggressive MB tumor subtypes are Group 3 medulloblastoma (G3MB), which are commonly characterized by overexpression of the driver oncogene c-MYC due to gene ampli fi - cation in 17% of cases 40,42,43 .”
InfluentialUnderstanding three-dimensional chromatin organization in diploid genomes
Li, J., Lin, Y., Tang, Q., & Li, M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.06.018 · Cited by 43
Immune cell landscape and immunotherapy of medulloblastoma
Zhang, J., & Wang, T. (2021) · Pediatric Investigation · doi:10.1002/ped4.12261 · Cited by 24
Self-citationChildhood Medulloblastoma: An Overview
Suk, Y., Gwynne, W. D., Burns, I., Venugopal, C., & Singh, S. K. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1952-0_1 · Cited by 32
Rossi, M., Talbot, J., Piris, P., Grand, M. L., Montero, M.-P., Matteudi, M., Agavnian, E., Appay, R., Keime, C., Williamson, D., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104149 · Cited by 23
Mynarek, M., Obrecht, D., Sill, M., Sturm, D., Kloth‐Stachnau, K., Selt, F., Ecker, J., von Hoff, K., Juhnke, B.-O., Goschzik, T., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02522-4 · Cited by 27
Self-citationModeling Human Brain Tumors and the Microenvironment Using Induced Pluripotent Stem Cells
Khamis, Z. I., Sarker, D. B., Xue, Y., Al-Akkary, N., James, V. D., Zeng, C., Li, Y., & Sang, Q. A. (2023) · Cancers · doi:10.3390/cancers15041253 · Cited by 24
The multiomic landscape of meningiomas: a review and update
Wang, J. Z., Nassiri, F., Landry, A., Patil, V. S., Liu, J., Aldape, K., Gao, A. F., & Zadeh, G. M. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04253-2 · Cited by 21
Wnt Signaling in Brain Tumors: A Challenging Therapeutic Target
Manfreda, L., Rampazzo, E., & Persano, L. (2023) · Biology · doi:10.3390/biology12050729 · Cited by 23
“Several molecular alterations have been described for this neoplasm, including isochromosome 17q (50% of cases), monosomy of chromosome 6, and Tumor Protein P53 (TP53), Patched 1 (PTCH1), and β-catenin (CTNNB1) gene mutations [150].”
BackgroundBrain Tumor Classification by Methylation Profile
Park, J. W., Lee, K., Kim, E. E., Kim, S., & Park, S. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e356 · Cited by 27
The therapeutic and diagnostic potential of regulatory noncoding RNAs in medulloblastoma
Joshi, P. K., Katsushima, K., Zhou, R., Meoded, A., Stapleton, S. L., Jallo, G. I., Raabe, E. H., Eberhart, C. G., & Perera, R. J. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz023 · Cited by 23
Targeting the medulloblastoma: a molecular-based approach.
Luzzi, S., Lucifero, A. G., Brambilla, I., Mantelli, S. S., Mosconi, M., Foiadelli, T., & Savasta, S. (2020) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v91i7-s.9958 · Cited by 31
“23-25 This novel molecular subgrouping has potential prognostic implications, so the current risk stratification divides the MBs in “low”, “standard”, “high”, and “very high risk”, based on age, presence of metastases, histologic phenotype, prognostic molecular markers, and especially, molecular subtype.(16-18) Table…”
BackgroundMedulloblastoma: an Old Diagnosis with New Promises
Szalontay, L., & Khakoo, Y. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00953-4 · Cited by 28
Pathology of the Tumors of the Central Nervous System
Bumci, R., Parthymos, I., Zamboglou, C., & GOUSSIA, A. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-33517-4_6 · Cited by 22
Rodríguez‐Blanco, J., Salvador, A., Suter, R. K., Swiderska‐Syn, M., Palomo-Caturla, I., Kliebe, V. M., Shahani, P. H., Peterson, K. D., Turos‐Cabal, M., Vieira, M. E., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci171136 · Cited by 24
“Despite these described differences, Minnelide demonstrated effectiveness in reducing the leptomeningeal spread of MYC -amplified MB, a characteristic feature present in nearly half of these tumors (4–6) and a key factor contributing to their unfavorable prognosis (15).”
BackgroundThe growing role of epigenetics in childhood cancers
Panditharatna, E., & Filbin, M. G. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000867 · Cited by 19
Chaturvedi, N. K., Kling, M. J., Griggs, C. N., Kesherwani, V., Shukla, M., McIntyre, E. M., Ray, S., Liu, Y., McGuire, T. R., Sharp, J. G., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0996 · Cited by 21
“Mol Cancer Ther; 19(6) June 2020 MOLECULAR CANCER THERAPEUTICS 1360”
BackgroundInfluentialSelf-citationMedulloblastoma drugs in development: Current leads, trials and drawbacks
Wen, J., & Hadden, M. K. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113268 · Cited by 22
Xue, Y., Fu, Y., Zhao, F., Gui, G., Li, Y., Rivero-Hinojosa, S., Liu, G., Li, Y.-Q., Xia, S., Eberhart, C. G., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0603 · Cited by 23
“A subset of group 3 patients with MB harbor MYC amplification or protein hyperexpression, also referred to as MYC-driven MB (8, 9).”
BackgroundResultSchoof, M., Godbole, S., Albert, T., Dottermusch, M., Walter, C., Ballast, A., Qin, N., Olivera, M. B., Göbel, C., Neyazi, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43564-w · Cited by 20
Self-citationChemical Modulation of WNT Signaling in Cancer
Zhang, L.-S., & Lum, L. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.11.008 · Cited by 26
Tamayo-Orrego, L., & Charron, F. (2019) · F1000Research · doi:10.12688/f1000research.20013.1 · Cited by 25
Coni, S., Magno, L. D., Serrao, S. M., Kanamori, Y., Agostinelli, E., & Canettieri, G. (2019) · Cells · doi:10.3390/cells8020150 · Cited by 22
Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation
Iorgulescu, J. B., Ziffle, J. V., Stevers, M., Grenert, J. P., Bastian, B. C., Chávez, L., Stichel, D., Buchhalter, I., Samuel, D., Nicolaides, T. P., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1819-x · Cited by 21
“The recurrent genetic alterations that characterize each of these four molecular subgroups have been described over the last few years [2, 5, 6, 8, 9].”
BackgroundMethodSelf-citationManubhai, K. P., Kumar, A., Biswas, D., Moiyadi, A. V., Shetty, P. M., Gupta, T., Epari, S., Shirsat, N. V., & Srivastava, S. (2021) · Brain Tumor Pathology · doi:10.1007/s10014-020-00391-x · Cited by 29
“Adult SHH tumors have been found to have a higher mutational burden in the SHH pathway-related genes and the chromatin modifier genes [3] Mutations in the promoter region of the TERT gene also predominantly occur in adult SHH medulloblastomas [5].”
BackgroundThe landscape of coding RNA editing events in pediatric cancer
Wen, J., Rusch, M., Brady, S. W., Shao, Y., Edmonson, M. N., Shaw, T. I., Powers, B. B., Tian, L., Easton, J. B., Mullighan, C. G., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08956-5 · Cited by 21
Self-citationPediatric Brain Tumors in the Molecular Era: Updates for the Radiologist
AlRayahi, J., Alwalid, O., Mubarak, W. M., Maaz, A. U. R., & Mifsud, W. (2022) · Seminars in Roentgenology · doi:10.1053/j.ro.2022.09.004 · Cited by 21
Mainwaring, O. J., Weishaupt, H., Zhao, M., Rosén, G., Borgenvik, A., Breinschmid, L., Verbaan, A. D., Richardson, S., Thompson, D., Clifford, S. C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36847-9 · Cited by 21
Astrocytes influence medulloblastoma phenotypes and CD133 surface expression
Gronseth, E. I., Gupta, A., Koceja, C., Kumar, S., Kutty, R. G., Rarick, K. R., Wang, L., & Ramchandran, R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235852 · Cited by 19
Takase, H., Tanoshima, R., Singla, N., Nakamura, Y., & Yamamoto, T. (2021) · Neurosurgical Review · doi:10.1007/s10143-021-01674-3 · Cited by 19
“It might not seem currently feasible; however, the recent success in the genomic study of medulloblastoma is encouraging for conducting time-consuming studies in rarer CNS tumors [38, 71, 72].”
BackgroundWarwick, T., Schulz, M. H., Gilsbach, R., Brandes, R. P., & Seuter, S. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac178 · Cited by 20
Rokita, J. L., Rathi, K. S., Cardenas, M., Upton, K. A., Jayaseelan, J. C., Cross, K. L., Pfeil, J., Ritenour, L. E., Modi, A., Farrel, A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/566455 · Cited by 19
Histopathology and molecular pathology of pediatric pineal parenchymal tumors
Vasiljevic, A. (2023) · Child's Nervous System · doi:10.1007/s00381-022-05637-x · Cited by 18
“These alterations are not specific to PPTIDs since they have also been demonstrated in some group 3 and group 4 medulloblastomas (21% of subtype II and 14% of subtype VII, respectively) [32].”
BackgroundRobbins, C. T., Bou-Dargham, M. J., Sanchez, K. G., Rosen, M. C., & Sang, Q. A. (2018) · Journal of Cancer · doi:10.7150/jca.27993 · Cited by 21
“There are some patients that do not have driving events associated with these DNA methylation subtypes for group 3 and 4 tumors warranting further investigation [60].”
InfluentialChen, X., Fan, Z., Li, K. K., Wu, G., Yang, Z. H., Gao, X., Liu, Y., Wu, H., Chen, H., Tang, Q., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa079 · Cited by 19
Self-citationNotch1 switches progenitor competence in inducing medulloblastoma
Ballabio, C., Gianesello, M., Lago, C., Okonechnikov, K., Anderle, M., Aiello, G., Antonica, F., Zhang, T., Gianno, F., Giangaspero, F., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd2781 · Cited by 19
“Mutations in NOTCH signaling genes have been described in Group 3 MB (Northcott et al., 2017), with especially elevated expression of NOTCH1 in spinal metastases (Kahn et al., 2018).”
BackgroundSelf-citationYang, L., & Ye, W. (2022) · Energy Reports · doi:10.1016/j.egyr.2022.09.052 · Cited by 18
Gojo, J., Kjærsgaard, M., von Zezschwitz, B., Capper, D., Tietze, A., Kool, M., Haberler, C., Pizer, B. L., & von Hoff, K. (2022) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2022.104660 · Cited by 18
Self-citationArthur, C., Jylhä, C., de Ståhl, T. D., Shamikh, A., Sandgren, J., Rosenquist, R., Nordenskjöld, M., Harila‐Saari, A. H., Barbany, G., Sandvik, U., et al. (2023) · Cancers · doi:10.3390/cancers15071972 · Cited by 20
Targeted treatment of solid tumors in pediatric precision oncology
Bertacca, I., Pegoraro, F., Tondo, A., & Favre, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176790 · Cited by 22
“APC pathogenic variants are generally identified in CTNNB1 wild-type tumors, explaining the WNT pathway activation (117).”
BackgroundGhasemi, D. R., Okonechnikov, K., Rademacher, A., Tirier, S. M., Maaß, K. K., Schumacher, H., Joshi, P. K., Gold, M. P., Sundheimer, J. K., Statz, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44117-x · Cited by 20
Self-citationTran, Q. T., Breuer, A. M., Lin, T., Tatevossian, R., Allen, S. J., Clay, M. R., Furtado, L. V., Chen, J., Hedges, D. J., Michael, T., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00718-3 · Cited by 24
“The ability to assay FFPE has facilitated the accumulation of large tumor cohorts and allows easy integration into standard clinical work fl ows 9,13,20 .”
BackgroundMethodSelf-citationTargeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine
Moreira, D. C., Venkataraman, S., Subramanian, A., DeSisto, J. A., Balakrishnan, I., Prince, E. W., Pierce, A. M., Griesinger, A. M., Green, A., Eberhardt, C. G., et al. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03457-0 · Cited by 27
Inter and intra-tumoral heterogeneity as a platform for personalized therapies in medulloblastoma
Danilenko, M., Clifford, S. C., & Schwalbe, E. C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107828 · Cited by 20
Pagnuzzi‐Boncompagni, M., Picco, V., Vial, V., Planas-Bielsa, V., Vandenberghe, A., Daubon, T., Derieppe, M., Montemagno, C., Durivault, J., Grépin, R., et al. (2021) · Cancers · doi:10.3390/cancers14010070 · Cited by 20
“Cancers of the central nervous system are the second most prevalent childhood tumors after hematologic cancer [2].”
BackgroundAging and senescence: Key players in brain tumor progression and drug resistance
Zhang, C., Neha, N., Zhang, J., Dhaha, P., Li, X., Mishra, S. K., Fleishman, J. S., Parvez, S., Jha, S. K., & Huang, M. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101228 · Cited by 21
Self-citationPò, A., Abballe, L., Sabato, C., Gianno, F., Chiacchiarini, M., Catanzaro, G., Smaele, E. D., Giangaspero, F., Ferretti, E., Miele, E., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082326 · Cited by 17
Medulloblastoma epigenetics and the path to clinical innovation
Haltom, A. R., Toll, S. A., Cheng, D., Maegawa, S., Gopalakrishnan, V., & Khatua, S. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03591-9 · Cited by 17
Tauziède‐Espariat, A., Huybrechts, S., Indersie, É., Dufour, C., Puget, S., Chivet, A., Roux, A., Pagès, M., Gareton, A., Chrétien, F., et al. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001640 · Cited by 20
Metadata
- Authors
- Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., Warnatz, H.-J., Sidiropoulos, N., Phillips, A. H., Schumacher, S., Kleinheinz, K., Waszak, S. M., Erkek, S., Jones, D. T. W., Worst, B. C., Kool, M., Zapatka, M., Jäger, N., Chavez, L., Hutter, B., Bieg, M., Paramasivam, N., Heinold, M., Gu, Z., Ishaque, N., Jäger-Schmidt, C., Imbusch, C. D., Jugold, A., Hübschmann, D., Risch, T., Amstislavskiy, V., Gonzalez, F. G. R., Weber, U. D., Wolf, S., Robinson, G. W., Zhou, X., Wu, G., Finkelstein, D., Liu, Y., Cavalli, F. M. G., Luu, B., Ramaswamy, V., Wu, X., Koster, J., Ryzhova, M., Cho, Y.-J., Pomeroy, S. L., Herold-Mende, C., Schuhmann, M., Ebinger, M., Liau, L. M., Mora, J., McLendon, R. E., Jabado, N., Kumabe, T., Chuah, E., Ma, Y., Moore, R. A., Mungall, A. J., Mungall, K. L., Thiessen, N., Tse, K., Wong, T., Jones, S. J. M., Witt, O., Milde, T., Von Deimling, A., Capper, D., Korshunov, A., Yaspo, M.-L., Kriwacki, R., Gajjar, A., Zhang, J., Beroukhim, R., Fraenkel, E., Korbel, J. O., Brors, B., Schlesner, M., Eils, R., Marra, M. A., Pfister, S. M., Taylor, M. D., & Lichter, P.
- Affiliations
- St. Jude Children's Research Hospital (US)
- German Cancer Research Center (DE)
- Hospital for Sick Children (CA)
- University of Copenhagen (DK)
- Massachusetts Institute of Technology (US)
- European Molecular Biology Laboratory (DE)
- Max Planck Institute for Molecular Genetics (DE)
- Broad Institute (US)
- Burdenko Neurosurgery Institute (RU)
- Oregon Health & Science University (US)
- Boston Children's Hospital (US)
- Universitätsklinikum Tübingen (DE)
- University Children's Hospital Tübingen (DE)
- University of California, Los Angeles (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Duke University (US)
- McGill University (CA)
- Kitasato University Hospital (JP)
- BC Cancer Agency (CA)
- University Hospital Heidelberg (DE)
- Corresponding author
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- ORCID
- Northcott, Paul A.
- Buchhalter, Ivo
- Morrissy, A. Sorana
- Hovestadt, Volker
- Weischenfeldt, Joachim
- Zichner, Thomas
- Rudneva, Vasilisa A.
- Warnatz, Hans-Jörg
- Sidiropoulos, Nikos
- Phillips, Aaron H.
- Schumacher, Steven
- Kleinheinz, Kortine
- Waszak, Sebastian M.
- Erkek, Serap
- Jones, David T. W.
- Kool, Marcel
- Zapatka, Marc
- Jäger, Natalie
- Hutter, Barbara
- Bieg, Matthias
- Paramasivam, Nagarajan
- Gu, Zuguang
- Ishaque, Naveed
- Imbusch, Charles D.
- Hübschmann, Daniel
- Amstislavskiy, Vyacheslav
- Robinson, Giles W.
- Zhou, Xin
- Wu, Gang
- Finkelstein, David
- Liu, Yanling
- Cavalli, Florence M. G.
- Ramaswamy, Vijay
- Wu, Xiaochong
- Ryzhova, Marina
- Cho, Yoon-Jae
- Pomeroy, Scott L.
- Schuhmann, Martin
- Ebinger, Martin
- Liau, Linda M.
- Mora, Jaume
- McLendon, Roger E.
- Jabado, Nada
- Kumabe, Toshihiro
- Moore, Richard A.
- Mungall, Andrew J.
- Wong, Tina
- Jones, Steven J. M.
- Witt, Olaf
- Milde, Till
- Capper, David
- Korshunov, Andrey
- Yaspo, Marie-Laure
- Kriwacki, Richard
- Gajjar, Amar
- Zhang, Jinghui
- Beroukhim, Rameen
- Fraenkel, Ernest
- Korbel, Jan O.
- Brors, Benedikt
- Schlesner, Matthias
- Eils, Roland
- Marra, Marco A.
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- Venue
- Nature
- Published
- 2017-07
- Volume
- 547
- Issue
- 7663
- Pages
- 311-317
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5905700
- OpenAlex
- W2737542366
- Cited by
- 1,112
- References
- 66
- Citations by year
- 2026: 63 · 2025: 132 · 2024: 125 · 2023: 154 · 2022: 142 · 2021: 148 · 2020: 120 · 2019: 120 · 2018: 94 · 2017: 12
- FWCI
- 54.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 19 d)
- Locations
- Nature (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Max Planck Digital Library (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Funders
- Alexander and Margaret Stewart Trust
- Pediatric Brain Tumor Foundation (R01CA159859)
- Deutsches Krebsforschungszentrum
- Genome Canada (R01CA159859)
- Children's Hospital Foundation
- Ontario Institute for Cancer Research
- American Lebanese Syrian Associated Charities
- Government of Ontario
- Genome British Columbia (R01CA159859)
- Canada Research Chairs
- Brain Tumour Charity (GN-000356)
- Bundesministerium für Bildung und Forschung (01KU1505E, 01KU1201A, 01KU1505A)
- Terry Fox Research Institute (R01CA159859)
- Deutsche Krebshilfe (109252)
- Hospital for Sick Children
- Stichting Kinderen Kankervrij
- BC Cancer Foundation (FDN-143288)
- Brain Tumour Research
- National Institutes of Health
- Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft
- Garron Family Cancer Centre
- National Cancer Institute (R01CA148699, R01CA109467, R01CA159859)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- medulloblastoma, molecular subtypes, driver mutations, somatic mutations, mutational signatures, enhancer hijacking, in-frame insertion, DNA methylation, Group 3 medulloblastoma, Group 4 medulloblastoma, therapeutic target, childhood brain tumours, integrative genomics
- MeSH terms
- Whole Genome Sequencing, Carrier Proteins, DNA Mutational Analysis, Epistasis, Genetic, Humans, Medulloblastoma, Muscle Proteins, Mutation, Oncogenes, Transcription Factors, Cohort Studies, Genome, Human, DNA Methylation, Genomics, Wnt Proteins, Molecular Targeted Therapy, Carcinogenesis, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.